FDA in­sid­er re­view of­fers a stel­lar en­dorse­ment for Bio­gen’s con­tro­ver­sial ad­u­canum­ab to treat Alzheimer’s — but sta­tis­ti­cal analy­sis mars the pic­ture

The FDA just pub­lished its re­view of Bio­gen’s ap­pli­ca­tion for the ap­proval of ad­u­canum­ab to treat Alzheimer’s, and reg­u­la­tors de­liv­ered a sol­id en­dorse­ment for us­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER